Состояние и перспективы разработки вакцин против пандемически опасных вирусов гриппа птиц

Обложка

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Суммированы данные о разработке вакцин против наиболее известных пандемически опасных вариантов вирусов гриппа А. Дан обзор эпидемиологической ситуации в мире в связи с появлением в циркуляции новых вариантов вирусов гриппа птиц различных подтипов, способных вызывать тяжелые заболевания у людей. Рассматривается ряд подходов к конструированию современных инактивированных и живых противогриппозных вакцин. Проведен сравнительный анализ свойств различных вакцинных препаратов и их роли в общем плане предпандемической подготовки.

Об авторах

Ю. А. Дешева

ГУ НИИ экспериментальной медицины РАМН

Автор, ответственный за переписку.
Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

Л. Г. Руденко

ГУ НИИ экспериментальной медицины РАМН

Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

Список литературы

  1. Александрова Г. И. Живая гриппозная вакцина в СССР: разработка, изучение и практическое использование // Новое в эпидемиологии и профилактике вирусных инфекций. Л., 1986. C. 66-83.
  2. Дешева Ю. А., Лу Х., Рекстин А. Р. и др. Подготовка реассортантных вакцинных штаммов для живой гриппозной вакцины против наиболее опасных вирусов гриппа - возможных возбудителей пандемии // Материалы Международной научной конференции «Актуальные вирусные инфекции - теоретические и практические аспекты». СПб., 2-5 ноября 2004 г. C. 36.
  3. Егоров А. Ю., Лисовская К. В. Высокорепродуктивные температурочувствительные рекомбинанты вируса гриппа А // Новое в эпидемиологии и профилактике вирусных инфекций. Л., 1986. С. 117-124.
  4. Aamir U., Naeem K., Ahmed S. Influenza infection caused by avian influenza virus H9N2 in humans // Abstract book of 2nd Orthomyxoviruses Research Conference. New Jersey, USA, 2003. Р. 12.
  5. Armerding D., Rossiter H., Ghazszouli I. et al. Evaluation of live and inactivated influenza A virus vaccines in a mouse model // J. Infect. Dis. 1982. Vol. 145. № 3. Р. 320–330.
  6. Avian influenza A(H5N1), 2004 // WHO Weekly Epidemiol. Rec. 2004. Vol. 79. P. 65-70.
  7. Banks J., Speidel E. S., Moore E. et al. Changes in the gaemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza virus in Italy // Arch. Virology. 2001. Vol. 146. № 5. Р. 963–973.
  8. Belshe R. B., Gruber W. C., Mendelman P. M. et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine // J. Peds. 2000. Vol. 136. P. 168-175.
  9. Bender C., Hall H., Huang J. et al. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from human in 1997-1998 // Virology. 1999. Vol. 254. P. 115-123.
  10. Brown E. G., Liu H., Chang Kit L. et al. Patterns of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: identification of functional themes / Proc. Natl. Acad. Sci. USA. 2001. Vol. 98. P. 6883-6888.
  11. Cameron K. R., Gregory V., Banks I. et al. H9N2 subtype influenza A viruses in poultry in Pakistam are closely related to the H9N2 viruses responsible for human infection in Hong Kong // Virology. 2000. Vol. 278. Р. 36–41.
  12. Chen H., Matsuoka Y., Chen Q. et al. Generation and characterization of an H9N2 cold-adapted reassortant as a vaccine candidate // Avian Dis. 2003. Vol. 47. Suppl. 3. Р. 1127–1130.
  13. Chen H., Subbarao K., Swayne D. et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate // Vaccine. 2003. Vol. 21. P. 1974-1979.
  14. Claas E., Osterhaus A., van Beek R. et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus // Lancet. 1998. Vol. 351. Р. 472–477.
  15. Demicheli V., Jefferson T., Rivetti D., Deeks J. Prevention and early treatment of influenza in healthy adults // Vaccine. 2000. Vol. 18. P. 957-1030.
  16. Desheva J. A., Rudenko L. G., Alexandrova G. I. et al. Reassortment between avian apathogenic and human attenuated cold-adapted viruses as an approach for preparing influenza pandemic vaccines // Options for the control of Influenza V/ Ed. Y. Kawaoka. Amsterdam: Elsevier, 2004. P. 724-727.
  17. Edwards L. E., Nguen D. C., Lu X. et al. Antigenic characteristics of recent avian influenza A (H5N1) viruses isolated from humans // Ibid. P. 109-113.
  18. Fodor E., Devenish L., Engelhardt O. G., Palese P. et al. Rescue of inluenza A virus from recombinant DNA // J. Virology. 1999. Vol. 73. № 11. Р. 9679–9682.
  19. Fouchier R. A., Schneeberger P. M., Rozendaal F. W. et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome // Proc. Natl. Acad. Sci. USA. 2004. Vol. 101. P. 1356-1361.
  20. Guan Y., Poon L. L., Cheung C. Y. et al. H5NI influenza: a protean pandemic threat // Proc. Nat. Acad. Sci. USA. 2004. Vol. 101. № 21. P. 8156-8161.
  21. Guan Y., Shortridge K. F., Krauss S. et al. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China // J. Virology. 2000. Vol. 74. № 20. Р. 9372–9380.
  22. Hatta M., Kawaoka Y. The continued pandemic threat posed by avian influenza viruses in Hong Kong // Trends in Microbiology. 2002. Vol. 10. № 7. Р. 340-344.
  23. Horimoto T., Rivera E., Pearson J. Origin and molecular changes associated with emergence of a highly pathogenic H5N2 influenza virus in Mexico // Virology. 1995. Vol. 213. Р. 223–230.
  24. Hovden A., Cox R. J., Haaheim L. H. The immune response to H7N1 whole virus vaccine in mice // Options for the control of Influenza V/ Ed. Y. Kawaoka. Amsterdam: Elsevier, 2004. P. 636-639.
  25. Katz J. M., Lim W., Bridges C. B. et al. Antibody response in individuals infected with avian inflenza A (H5N1) viruses and detection of antiH5 antibody among household and social contacts // J. Infect. Dis. 1999. Vol. 180. P. 1763-1770.
  26. Kawaoka Y., Krauss S., Webster R. G. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics // J. Virology. 1989. Vol. 63. P. 4603-4608.
  27. Kendal A. P. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? // Eur. J. Epid. 1997. Vol. 13. P. 591-609.
  28. Kendal A. P., Maassab H. F., Alexandrova G. I. et al. Development of cold-adapted recombinant live, attenuated influenza vaccines in USA and USSR // Antiviral Res. 1981. Vol. 1. P. 339-365.
  29. Klimov A. I., Cox N. J., Yotov W. V. et al. Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57 (H2N2) virus // Virology. 1992. Vol. 186. P. 795-797.
  30. Klimov A. I., Kiseleva I.V., Desheva J. A. et al. Live attenuated reassortant influenza vaccine prepared using A/Leningrad/134/17/57 (H2N2) donor strain is genetically stable after replication in children 3-6 years of age // Options for the control of influenza IV/ Eds. A. Osterhaus et al. Amsterdam: Excerpta Medica, 2001. P. 951–954.
  31. Klimov A. I., Rudenko L. G., Egorov A. Y. et al. Genetic stability of Russian cold-adapted live attenuated reassortant influenza vaccines // Options for the Control of Influenza III/ Eds. L. E. Brown et al. Amsterdam: Elsevier Science, 1996. P. 129-136.
  32. Kurtz J., Manwell R. J., Banks J. Avian influenza virus isolated from a woman with conjunctivitis // Lancet. 1996. Vol. 348. P. 901-902.
  33. Li K. S., Guan Y., Wang J. et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in Eastern Asia // Nature. 2004. Vol. 430. Р. 209-213.
  34. Li S., Liu C., Klimov A. et al. Recombinant influenza A virus vaccine for the pathogenic human A/Hong Kong/97(H5N1) viruses // J. Infect. Dis. 1998. Vol. 179. № 5. Р. 1132–1138.
  35. Lin Y. P., Shaw M., Gregory V. et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 9654-9658.
  36. Lipatov A., Webby R., Perez D. R. et al. Mouse studies of the efficacy of two modified H5 influenza A vaccines produced by reverse genetics // Abstract book of 2nd. Orthomyxoviruses Research Conference. New Jersey, USA, 2003. P. 35.
  37. Lu X., Renshaw M., Tumpey T. M. et al. Immunity to influenza A(H9N2) viruses induced by infection and vaccination // J. Virology. 2001. Vol. 75. P. 4896–4901.
  38. Major D. L., Newman R. W., Dunleavy U. et al. Evaluation of H9N2 influenza vaccines in Balb/c mice // Options for the control of influenza IV/ Eds. A. Osterhaus et al. Amsterdam: Excerpta Medica, 2001. Р. 784-794.
  39. Matrosovich M. N., Krauss S., Webster R. G. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity / Virology. 2001. Vol. 281. № 2. Р. 156-162.
  40. Matsuoka Y., Chen H., Cox N. et al. Safety evaluation in chickens of candidate human vaccines as potential pandemic strains of influenza // Avian Dis. 2003. Vol. 47. Suppl. 3. P. 926-930.
  41. Meltzer M., Cox N. J., Fukida K. The economic impact of pandemic influenza in the United States: priorities for intervention // Emerging Infect. Dis. 1999. Vol. 5. P. 659–671.
  42. Monto A. Interrupting the transmission of respiratory tract infections: theory and practice / Clinical Infect. Dis. 1999. Vol. 28. Р. 200–204.
  43. Munster V., de Wit E., Kuiken T. et al. The outbreak of H7N7 highly pathogenic avian influenza in the Netherlands // Abstract book of 2nd. Orthomyxoviruses Research Conference. New Jersey, USA, 2003. Р. 9.
  44. Nicholson K. G., Colegate A. E., Podda A. et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/ 97(H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza // Lancet. 2001. Vol. 357. P. 1937-1943.
  45. Palker T., Kiseleva I., Youil R. et al. Immunogenicity and protective efficacy of intranasal coldadapted influenza A/New Caledonia vaccines comprised of egg- or cell culture-derived reassortants // Abstract book of «Negative strand viruses». Conference, Piza, Italy, 2003. P. 218.
  46. Peiris M., Yuen K. Y., Leung C. W. et al. Human infection with inluenza H9N2 // Lancet. 1999. Vol. 354. Р. 916-917.
  47. Potter C. W. A history of influenza // J. Appl. Microbiol. 2001. Vol. 91. P. 572-579.
  48. Powers D. C., Smith G. E., Anderson E. L. et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults // J. Infect. Dis. 1995. Vol. 171. P. 1595-1598.
  49. Production of pilot lots of inactivated influenza vaccine in response to a pandemic threat: an interim biosafety risk assessment // WHO Weekly epidemiological rec. 2003. Vol. 78. Р. 405–408.
  50. Rowe T., Abernathy R. A., Hu-Primmer J. et al. Detection of antibody to avian influenza A(H5N1) virus in human serum by using a combination of serologic assays // J. of Clinical. Microbiology. 1999. Vol. 37. P. 937-943.
  51. Rudenko L. G., Alexandrova G. I. Current strategies for the prevention of influenza by the Russian cold-adapted live influenza vaccine among different populations // Options for the control of influenza IV / Eds. A. Osterhaus et al. Amsterdam: Excerpta Medica, 2001. P. 945-950.
  52. Rudenko L. G., Slepushkin A. N., Monto A. S. et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their inactivated contacts in Novgorod, Russia // J. Infect. Dis. 1993. Vol. 168. Р. 881–887.
  53. Saito T., Lim W., Suzuki T. et al. Characterization of a human H9N2 influenza virus isolated in Hong Kong // Vaccine. 2002. Vol. 20. Р. 125–133.
  54. Sellek P. W., Gleeson L. J., Hooper P. T. et al. Identification and characterization of an H7N3 influenza virus from outbreak of virulent avian influenza in Victoria // Aust. Vet. J. 1997. Vol. 52. № 4. Р. 289–292.
  55. Seo S. H., Hoffmann E., Webster G. R. Lethal H5N1 influenza viruses escape host antiviral cyokine responses // Nature Medicine. 2002. Vol. 8. № 9. Р. 950–954.
  56. Stephenson I., Nicholson K. G., Colegate A. et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population // Vaccine. 2003. Vol. 21. P. 1687-1693.
  57. Stephenson I., Nicholson K. G., Gluck R. et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99(H9N2) vaccine in healthy adults: phase I randomized trial // Lancet. 2003. Vol. 362. P. 1959-1966.
  58. Stephenson I., Wood J. M., Nicholson K. G. et al. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin // J. Med. Virology. 2003. Vol. 70. № 3. Р. 391-398.
  59. Suarez D. L., Perdue M. L., Cox N. et al. Comparisons of highly virulent H5N1 influenza viruses isolated from humans and chickens from Hong Kong // J. Virology. Vol. 72. № 8. Р. 6678–6688.
  60. Subbarao K., Klimov A., Katz J. et al. Characterization of an avian influenza A(H5N1) virus isolated from a child with a fatal respiratory illness // Science. 1998. Vol. 279. Р. 393–396.
  61. Subbarao K., Chen H., Swayne D. et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics // Virology. 2003. Vol. 305. Р. 192-200.
  62. Takada A., Kuboki N., Okazaki K. et al. Avirulent avian influenza virus as a vaccine strain against a potential human pandemic // J. Virology. 1999. Vol. 73. № 10. Р. 8303–8307.
  63. Taubenberger J. K., Reid A. H., Janczewsky T. A. et al. Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus // Phil. Trans. R. Soc. 2001. Vol. 356. P. 1829-1839.
  64. Tran T. H., Nguen T. L., Nguen T. D. et al. Avian influenza A(H5N1) in 10 patients in Vietnam // The New Eng. J. of Med. 2004. Vol. 350. P. 1179-1188.
  65. Treanor J. J., Wilkinon B. E., Masseoud F. et al. Safety and immunogenicity of a recombinant haemagglutinin vaccine for H5 influenza in humans // Vaccine. 2001. Vol. 19. Р. 1792-1797.
  66. Viseshakul N., Thanawongnuwech R., Amonsin A. et al. The genome sequence analysis of H5N2 avian influenza A virus isolated from the outbreak among poultry populations in Thailand //Virology. 2004. Vol. 328. P. 169–176.
  67. Webster R. G., Bean W. J., Gorman T. M. et al. Evolution and ecology of influenza A viruses // Microbiol. Rev. 1992. Vol. 56. Р. 152-179.
  68. WHO memorandum // Bull. WHO. 1995. Vol. 73. P. 431-435.
  69. Wood J. M., Major D., Newman R. W. et al. Preparation of vaccines against H5N1 influenza // Vaccine. 2002. Vol. 20. P. S84-S87.
  70. Wright P. F., Webster R. G. Orthomyxoviruses // Fields, Virology / Eds. Knipe et al. Philadelphia: Lippincott Williams and Wilkins, 2001. P. 1533-1579.
  71. Yuen K. Y., Chan P. K., Peiris M. et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus // Lancet. 1998. Vol. 351. Р. 467-471.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Эко-Вектор, 2005


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.